Dr. Frank M. Torti, M.D., MPH has just been appointed as the Acting Commissioner of Food and Drugs (FDA). He has been a prominent clinician, scientist and researcher in molecular oncology. Until his appointment at the FDA as Principal Deputy Commissioner and first Chief Scientist in April 2008, Dr. Torti had served the as Charles L. Spurr Professor of Medicine, Chair of the Department of Cancer Biology, and Director of the Comprehensive Cancer Center at Wake Forest University School of Medicine in Winston-Salem, N.C.
Dr. Torti received his bachelor’s and master’s from Johns Hopkins University, his medical degree from Harvard Medical School, and his Master of Public Health from Harvard School of Public Health. He served as an intern and resident at Beth Israel Hospital in Boston, and a fellow of medical oncology at Stanford University where he subsequently joined the faculty and was tenured. He has written extensively on prostate and bladder cancer, designed and executed a number of cancer clinical trials, and has substantially contributed to the understanding of the molecular mechanisms that underlie inflammatory diseases and cancer.
Throughout his career, Dr. Torti has served on and chaired a number of national health and medical committees. He has also served on the National Institutes of Health’s National Advisory Council for Complementary and Alternative Medicine as well as being the founder and first President of the Cancer Biology Training Consortium, a national society of cancer biology department chairs and program directors. He is the recipient of a National Institutes of Health MERIT Award.
Dr. Torti has released the following press statement inviting public comment about the FDA. I am working with members of Malecare to fashion a response to his invitation. I invite, no I encourage, both individuals and organizations concerned about the fight against prostate cancer to take advantage oh his invitation and send him an email expressing our concerns about drug approval.
Comments to Dr. Torti should be sent to: firstname.lastname@example.org
Here is Dr. Torti’s first statement and his invitation to forward comments:
“I am using this first communication as an opportunity to introduce, in my own words, some thoughts about the FDA. I will develop these in more detail in subsequent communications. I intend these comments to communicate both to my colleagues at the FDA and to our many constituencies.
I will need your help. The job of Acting Commissioner is more difficult (if that is possible) than that of the Commissioner. For many issues, we await the guidance of our new administration. This is as it should be, and we embrace the opportunity to help them implement their vision for the FDA. Yet the work at FDA must be neither tentative nor delayed. Rather, we must steer the Agency with continued energy, enthusiasm and insight. We must continue to apply scientific thought and process to our regulatory decisions – based, as always, on the laws that govern our food and drugs.
To our consumers, we promise to provide you with clear, timely and accurate information on the risks and benefits of the products we regulate, earn your respect and trust, and further build a reputation for rock solid integrity, accuracy and transparency. For many issues of risk, science does not give us all the answers. When we do not yet know the answers, the FDA will be honest and forthcoming about our uncertainty.
To members of Congress and others who oversee our Agency, we need your partnership to reshape the agency and to provide us with the resources and legislative authorities necessary to support our work.
To our academic community and our medical, scientific and other professionals, we want to engage you to a much greater extent than before to help us tackle the difficult scientific problems that underpin FDA regulation.
To the companies we regulate, we acknowledge and respect the creativity and imagination involved in the development of your products, many of which began at our great academic institutions. You represent the essence of what has made America a great economic force and set us apart as a people, as Americans: creativity and focus. We promise you that our deliberations will be completed with respect, diligence and speed, but always remembering the old, but wise admonition of Hippocrates, to first do no harm.
To our own large family of FDA colleagues, we must continue to develop an environment in which scientific discourse and at times disagreement is accepted and respected, where politics has no standing in regulatory decisions, and where excellence is rewarded. We must be open to criticism, willing to change, and apply our decisions with humility and courtesy, bearing in mind that our sometimes imperfect judgments profoundly affect not only the fate of companies but the health and welfare of all Americans.
I want you to know that my door remains open. For the public, I welcome your feedback to the email address email@example.com for your questions, recommendations and insights.
I look forward to serving you during this transition.
Frank M. Torti, M.D., MPH
Acting Commissioner of Food and Drugs”
Joel T Nowak MA, MSW
This sounds very auspicious — it seems like Dr. Torti has the perfect background to potentially be of help to the PC community.
I knew the FDA was due for a major overhaul, especially because of conflicts of interest. But I’m not familiar with the other issues in contention, so I hope you will post Malecare’s “talking points” to give us an idea what to write about.
Talking points and the concerns of Malecare were post on the blog today, January 26th.